How We View CVS' Evolution
The firm has new approaches to managing healthcare needs.
Jake Strole: Within our healthcare coverage, CVS Health trades at one of the steepest discounts to our estimate of intrinsic value. With the stock near $60 per share versus our fair value estimate of $92, we think this narrow-moat name represents compelling value for long-term investors.
CVS Health transformed its business with its acquisition of Aetna in late 2018. The addition of a managed-care franchise to CVS' leading presence in retail pharmacy and pharmacy benefits management underpins our positive trend rating on the name, along with our optimistic outlook regarding valuation. The combination sets the stage for CVS to improve its cost position relative to less-integrated peers, while developing a stronger network effect as management looks to better leverage its retail footprint. Management's strategy to develop more clinically relevant stores, or so-called "health hubs," within its network puts the firm in a position to better manage its members' healthcare needs and potentially bend the medical benefits cost curve at Aetna over time. We think management's vision is very much akin to the integrated strategy pursued by UnitedHealth that forms the basis for its wide economic moat, leaving us similarly bullish on the future prospects for CVS. That said, execution over the next several years will remain paramount to generating shareholder value from the transaction and validating our thesis on the future competitive position of the organization.
Jake Strole does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.